Brief: Rallybio Corp - Phase 1 Study Of Rlyb116 Ongoing Initial Single Dose Safety, PK, And PD Data Expected For 30 Mg Dose In 4Q 2022

Rallybio

08/08/2022 13:23

Aug 8 (Reuters) - Rallybio Corp  RLYB.O :
    * RALLYBIO REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS
    * PHASE 1 STUDY OF RLYB116 ONGOING; INITIAL SINGLE DOSE
SAFETY,
PK, AND PD DATA EXPECTED FOR 30 MG DOSE IN 4Q 2022
    * AS OF JUNE 30, 2022, CASH, CASH EQUIVALENTS, AND
MARKETABLE
SECURITIES WERE $147.4 MILLION
    * NET LOSS WAS $17.6 MILLION FOR Q2 OF 2022, OR NET LOSS PER
COMMON SHARE OF $0.57
    * Q2 EARNINGS PER SHARE VIEW $-0.60 -- REFINITIV IBES DATA

Source text for Eikon:  ID:nBw3vLY5xa 
Further company coverage:  RLYB.O 

 ((Reuters.Briefs@thomsonreuters.com;))